CoChat

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

This report addresses whether small molecules can deplete FoxP3-expressing regulatory T (T reg) cells, thereby augmenting antitumor immunity. Imatinib, a tyrosine kinase inhibitor of oncogenic BCR-ABL protein expressed by chronic myelogenous leukemia (CML) cells, possesses off-targets including LCK expressed in T cells. We showed that imatinib-treated CML patients in complete molecular remission (CMR) exhibited selective depletion of effector T reg (eT reg) cells and significant increase in effector/memory CD8+ T cells while non-CMR patients did not. Imatinib at CML-therapeutic concentrations indeed induced apoptosis specifically in eT reg cells and expanded tumor antigen-specific CD8+ T cells in vitro in healthy individuals and melanoma patients, and suppressed colon tumor growth in vivo in mice. Mechanistically, because of FoxP3-dependent much lower expression of LCK and ZAP-70 in T reg cells compared with other T cells, imatinib inhibition of LCK further reduced their TCR signal intensity, rendering them selectively susceptible to signal-deprived apoptotis. Taken together, eT reg cell depletion by imatinib is instrumental in evoking effective immune responses to various cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20191009

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Reduction of T reg cells, particularly eT reg cells, by imatinib treatment. (A) Representative CD45RA and FoxP3 staining of CD4+ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B) Frequencies of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). Data are pooled from more than two independent experiments. (C) Correlation evaluated by ROC curves between CMR achievement and decrease of total and each subset (Fr. I, II, and III) of FoxP3+ T cells from CML patients’ PBMCs in B. Horizontal lines in B indicate medians. Statistical significance was assessed by Mann-Whitney U test in B.
Figure 1. Reduction of T reg cells, particularly eT reg cells, by imatinib treatment. (A) Representative CD45RA and FoxP3 staining of CD4+ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B) Frequencies of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). Data are pooled from more than two independent experiments. (C) Correlation evaluated by ROC curves between CMR achievement and decrease of total and each subset (Fr. I, II, and III) of FoxP3+ T cells from CML patients’ PBMCs in B. Horizontal lines in B indicate medians. Statistical significance was assessed by Mann-Whitney U test in B.CC BY-NC-SA · PubMed Central
Figure S1. Reduction of T reg cells, especially eT reg cells, by chronic imatinib treatment. (A) Frequencies of total CD4+ and CD8+ T cells in PBMCs of healthy donors (HD; n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 1 B. (B) The numbers of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 1 B. (C) Kinetics of the frequencies of total FoxP3+ T cells and each subset (Fr. I, II, and III) among CD4+ T cells in a CML patient from whom sufficient amounts of PBMCs during clinical course were obtained. Data are pooled from at least two independent experiments. Horizontal lines indicate medians. Statistical significance was assessed by Mann–Whitney U test.
Figure S1. Reduction of T reg cells, especially eT reg cells, by chronic imatinib treatment. (A) Frequencies of total CD4+ and CD8+ T cells in PBMCs of healthy donors (HD; n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 1 B. (B) The numbers of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 1 B. (C) Kinetics of the frequencies of total FoxP3+ T cells and each subset (Fr. I, II, and III) among CD4+ T cells in a CML patient from whom sufficient amounts of PBMCs during clinical course were obtained. Data are pooled from at least two independent experiments. Horizontal lines indicate medians. Statistical significance was assessed by Mann–Whitney U test.CC BY-NC-SA · PubMed Central
Figure S2. Frequencies of T reg cells and CD8+ T cell subsets under imatinib treatment, nilotinib treatment, or after switching to nilotinib from imatinib. (A and B) Frequencies of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of CML patients in CMR or non-CMR after nilotinib treatment (A, n = 4) or of CML patients who achieved CMR after switching from imatinib to nilotinib (B, n = 5). (C) The numbers of naive, central/memory, effector/memory, and terminally differentiated CD8+ T cells in the blood from CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 2 B. (D and E) CTLA-4 and TIM-3 expressions by CD8+ T cells (D) and the frequency of CTLA-4–positive or Tim-3–positive cells (E) in PBMCs of healthy donors (HD; n = 14 or 10) and CML patients in CMR (n = 27) or non-CMR (n = 20). Analyses in E were performed in patients from whom sufficient numbers of PBMCs were available. Data are pooled from at least two independent experiments. Horizontal lines in A, C, and E indicate medians. Statistical significance was assessed by Mann–Whitney U test.
Figure S2. Frequencies of T reg cells and CD8+ T cell subsets under imatinib treatment, nilotinib treatment, or after switching to nilotinib from imatinib. (A and B) Frequencies of total FoxP3+ T cells and each subset (Fr. I, II, III, IV, and V) among CD4+ T cells from PBMCs of CML patients in CMR or non-CMR after nilotinib treatment (A, n = 4) or of CML patients who achieved CMR after switching from imatinib to nilotinib (B, n = 5). (C) The numbers of naive, central/memory, effector/memory, and terminally differentiated CD8+ T cells in the blood from CML patients in CMR (n = 51) or non-CMR (n = 42) as in Fig. 2 B. (D and E) CTLA-4 and TIM-3 expressions by CD8+ T cells (D) and the frequency of CTLA-4–positive or Tim-3–positive cells (E) in PBMCs of healthy donors (HD; n = 14 or 10) and CML patients in CMR (n = 27) or non-CMR (n = 20). Analyses in E were performed in patients from whom sufficient numbers of PBMCs were available. Data are pooled from at least two independent experiments. Horizontal lines in A, C, and E indicate medians. Statistical significance was assessed by Mann–Whitney U test.CC BY-NC-SA · PubMed Central
Figure 2. General activation of CD8+ T cells under chronic imatinib treatment. (A) Representative staining for CD45RA and CCR7 to assess naive, central memory, effector memory, and terminally differentiated CD8+ T cells in PBMCs from a healthy donor (HD) and CML patients in CMR or non-CMR. (B) Frequencies of each subset among CD8+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). Data are pooled from more than two independent experiments. (C and D) IFN-γ and IL-2 production by CD8+ T cells stimulated with PMA and ionomycin. Representative staining of intracellular cytokines (C) and percentages (D) of cytokine-producing cells in CD8+ T cells from healthy donors (n = 15) and CML patients in CMR (n = 23) or non-CMR (n = 20). Data are pooled from more than two independent experiments. (E and F) Expression of cell surface markers for T cell exhaustion. (E) Representative PD-1 and LAG-3 staining of CD8+ T cells in the blood from a healthy donor and CML patients in CMR or non-CMR. (F) Frequencies of PD-1–positive and LAG-3–positive CD8+ T cells from PBMCs of healthy donors (n = 14) and CML patients in CMR (n = 28) or non-CMR (n = 21). Horizontal lines in B and F indicate medians. Analyses in C–F were performed in patients from whom sufficient numbers of PBMCs were available. Statistical significance was assessed by Mann-Whitney U test in B and F.
Figure 2. General activation of CD8+ T cells under chronic imatinib treatment. (A) Representative staining for CD45RA and CCR7 to assess naive, central memory, effector memory, and terminally differentiated CD8+ T cells in PBMCs from a healthy donor (HD) and CML patients in CMR or non-CMR. (B) Frequencies of each subset among CD8+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). Data are pooled from more than two independent experiments. (C and D) IFN-γ and IL-2 production by CD8+ T cells stimulated with PMA and ionomycin. Representative staining of intracellular cytokines (C) and percentages (D) of cytokine-producing cells in CD8+ T cells from healthy donors (n = 15) and CML patients in CMR (n = 23) or non-CMR (n = 20). Data are pooled from more than two independent experiments. (E and F) Expression of cell surface markers for T cell exhaustion. (E) Representative PD-1 and LAG-3 staining of CD8+ T cells in the blood from a healthy donor and CML patients in CMR or non-CMR. (F) Frequencies of PD-1–positive and LAG-3–positive CD8+ T cells from PBMCs of healthy donors (n = 14) and CML patients in CMR (n = 28) or non-CMR (n = 21). Horizontal lines in B and F indicate medians. Analyses in C–F were performed in patients from whom sufficient numbers of PBMCs were available. Statistical significance was assessed by Mann-Whitney U test in B and F.CC BY-NC-SA · PubMed Central
Figure S3. CD4+ T cell subsets under chronic imatinib treatment. (A) Representative staining for CD45RA and CCR7 to detect naive, central memory, effector memory, and terminally differentiated CD4+ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B and C) Frequencies (B) and the absolute numbers (C) of each subset among CD4+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). (D and E) IFN-γ and IL-2 production by CD4+ T cells stimulated with PMA and ionomycin. Representative staining (D) and percentages (E) of cytokine-producing cells among CD4+ T cells from healthy donors (n = 15) and CML patients with CMR (n = 23) or non-CMR (n = 20). (F) Expression of exhausted markers. Frequencies of PD-1–positive or LAG-3–positive CD4+ T cells from PBMCs of CML patients in CMR (n = 28) or non-CMR (n = 21). Analyses in E and F were performed in patients from whom sufficient numbers of PBMCs were available. Data are pooled from more than two independent experiments. Horizontal lines in B, C, E, and F indicate medians. Statistical significance was assessed by Mann–Whitney U test. ns, not significant; *, P < 0.05; **, P < 0.01.
Figure S3. CD4+ T cell subsets under chronic imatinib treatment. (A) Representative staining for CD45RA and CCR7 to detect naive, central memory, effector memory, and terminally differentiated CD4+ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B and C) Frequencies (B) and the absolute numbers (C) of each subset among CD4+ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). (D and E) IFN-γ and IL-2 production by CD4+ T cells stimulated with PMA and ionomycin. Representative staining (D) and percentages (E) of cytokine-producing cells among CD4+ T cells from healthy donors (n = 15) and CML patients with CMR (n = 23) or non-CMR (n = 20). (F) Expression of exhausted markers. Frequencies of PD-1–positive or LAG-3–positive CD4+ T cells from PBMCs of CML patients in CMR (n = 28) or non-CMR (n = 21). Analyses in E and F were performed in patients from whom sufficient numbers of PBMCs were available. Data are pooled from more than two independent experiments. Horizontal lines in B, C, E, and F indicate medians. Statistical significance was assessed by Mann–Whitney U test. ns, not significant; *, P < 0.05; **, P < 0.01.CC BY-NC-SA · PubMed Central
Figure S4. Effects of imatinib on LGLs, MDSCs, and proliferations of naive and effector CD4+ and CD8+ T cells. (A) The frequencies (top) and the numbers (bottom) of NK (CD3−CD16+CD56dimCD57+) and T (CD3+CD8+CD57+)-LGLs in the blood from CML patients in CMR (n = 21) or non-CMR (n = 20). (B) Frequency of granulocytic MDSCs (CD15+CD33+CD11b+HLA-DR−) and monocytic MDSCs (CD14+HLA-DR−) in the blood from CML patients in CMR (n = 23) or non-CMR (n = 20). (C) Frequency of CD11c+ MHC class IIhigh dendritic cells among CD3− cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). (D) Expressions of CD86 and CD40 by dendritic cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). Analyses were performed in patients from whom sufficient numbers of PBMCs were available. MFI, mean fluorescence intensity. (E and F) Proliferations of naive and effector subsets of CD4+ (E) and CD8+ (F) T cells prepared from PBMCs of healthy donors. Cells were stimulated with anti-CD3 and anti-CD28 mAbs with graded doses of imatinib (n = 5 each) for 5 d and assessed by CFSE dilution. CCR7+CD45RA+ as naive, CCR7+CD45RA− as central memory (CM), and CCR7−CD45RA− as effector memory (EM) T cells. (G and H) Effects of imatinib on cytokine production. CD8+ T cells from PBMCs of healthy donors (n = 6) were stimulated with PMA and ionomycin with graded doses of imatinib, and cytokine production was assessed by intracellular cytokine staining; IFN-γ and/or TNFα (G), and IFN-γ and/or IL-2 (H). Data are pooled from at least two independent experiments. Horizontal lines indicate medians in A–C. Statistical significance was assessed by Mann-Whitney U test in A–D or by two-way ANOVA with Holm-Sidak multiple comparisons to CD4+ T cells in E, CD8+ T cells in F, or each cytokine at 0 µM imatinib dose in G and H. Error bars indicate means ± SEM in D–H. ns, not significant; *, P < 0.05.
Figure S4. Effects of imatinib on LGLs, MDSCs, and proliferations of naive and effector CD4+ and CD8+ T cells. (A) The frequencies (top) and the numbers (bottom) of NK (CD3−CD16+CD56dimCD57+) and T (CD3+CD8+CD57+)-LGLs in the blood from CML patients in CMR (n = 21) or non-CMR (n = 20). (B) Frequency of granulocytic MDSCs (CD15+CD33+CD11b+HLA-DR−) and monocytic MDSCs (CD14+HLA-DR−) in the blood from CML patients in CMR (n = 23) or non-CMR (n = 20). (C) Frequency of CD11c+ MHC class IIhigh dendritic cells among CD3− cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). (D) Expressions of CD86 and CD40 by dendritic cells from PBMCs of CML patients in CMR or non-CMR (n = 8 each). Analyses were performed in patients from whom sufficient numbers of PBMCs were available. MFI, mean fluorescence intensity. (E and F) Proliferations of naive and effector subsets of CD4+ (E) and CD8+ (F) T cells prepared from PBMCs of healthy donors. Cells were stimulated with anti-CD3 and anti-CD28 mAbs with graded doses of imatinib (n = 5 each) for 5 d and assessed by CFSE dilution. CCR7+CD45RA+ as naive, CCR7+CD45RA− as central memory (CM), and CCR7−CD45RA− as effector memory (EM) T cells. (G and H) Effects of imatinib on cytokine production. CD8+ T cells from PBMCs of healthy donors (n = 6) were stimulated with PMA and ionomycin with graded doses of imatinib, and cytokine production was assessed by intracellular cytokine staining; IFN-γ and/or TNFα (G), and IFN-γ and/or IL-2 (H). Data are pooled from at least two independent experiments. Horizontal lines indicate medians in A–C. Statistical significance was assessed by Mann-Whitney U test in A–D or by two-way ANOVA with Holm-Sidak multiple comparisons to CD4+ T cells in E, CD8+ T cells in F, or each cytokine at 0 µM imatinib dose in G and H. Error bars indicate means ± SEM in D–H. ns, not significant; *, P < 0.05.CC BY-NC-SA · PubMed Central
Figure 3. Imatinib selectively reduces eT reg cells in vitro. (A) Proliferation inhibition and apoptosis induction by imatinib, dasatinib, and nilotinib. Subsets of CD4+ T cells (Fr. I and II and FoxP3− T cells) and CD8+ T cells prepared from PBMCs of healthy donors were stimulated with anti-CD3 and anti-CD28 mAbs with graded doses of imatinib (n = 8), dasatinib (n = 5), or nilotinib (n = 5) for 5 d. Proliferation was assessed by CFSE dilution and apoptosis by Annexin V and 7-AAD staining. Half-maximal inhibitory concentration (IC50) for proliferation and half-maximal effective concentration (EC50) for apoptosis are shown. Gray boxes indicate therapeutic doses. Data are pooled from more than two independent experiments. (B and C) Ki-67 staining of indicated subsets in freshly obtained PBMCs of a healthy individual (B, left; representative of five samples) and Ki-67 staining of Fr. II eT reg cells cultured with or without imatinib and 5 U/ml IL-2 for 5 d (B, right; two typical staining patterns representative of 10 samples in C). TCM, central memory T; TEM, effector memory T; TD, terminally differentiated. Percentages of Ki-67+ cells are indicated. Fold differences (C) in Ki-67+ eT reg frequencies after the culture in B. Donor samples (thin lines) were clustered by hierarchical clustering and K-means clustering into two groups. An insensitive group (red) with higher cluster means (bold red) and sensitive group (blue) with lower cluster means (bold blue) at 5 and 10 µM imatinib doses (n = 20). Data are pooled from more than two independent experiments. Error bars indicate means ± SEM in A. Statistical significance was assessed by two-way ANOVA with Holm-Sidak multiple comparisons to CD8+ T cells in A, and between two clustered groups at each dose in C. *, P < 0.05; ****, P < 0.0001.
Figure 3. Imatinib selectively reduces eT reg cells in vitro. (A) Proliferation inhibition and apoptosis induction by imatinib, dasatinib, and nilotinib. Subsets of CD4+ T cells (Fr. I and II and FoxP3− T cells) and CD8+ T cells prepared from PBMCs of healthy donors were stimulated with anti-CD3 and anti-CD28 mAbs with graded doses of imatinib (n = 8), dasatinib (n = 5), or nilotinib (n = 5) for 5 d. Proliferation was assessed by CFSE dilution and apoptosis by Annexin V and 7-AAD staining. Half-maximal inhibitory concentration (IC50) for proliferation and half-maximal effective concentration (EC50) for apoptosis are shown. Gray boxes indicate therapeutic doses. Data are pooled from more than two independent experiments. (B and C) Ki-67 staining of indicated subsets in freshly obtained PBMCs of a healthy individual (B, left; representative of five samples) and Ki-67 staining of Fr. II eT reg cells cultured with or without imatinib and 5 U/ml IL-2 for 5 d (B, right; two typical staining patterns representative of 10 samples in C). TCM, central memory T; TEM, effector memory T; TD, terminally differentiated. Percentages of Ki-67+ cells are indicated. Fold differences (C) in Ki-67+ eT reg frequencies after the culture in B. Donor samples (thin lines) were clustered by hierarchical clustering and K-means clustering into two groups. An insensitive group (red) with higher cluster means (bold red) and sensitive group (blue) with lower cluster means (bold blue) at 5 and 10 µM imatinib doses (n = 20). Data are pooled from more than two independent experiments. Error bars indicate means ± SEM in A. Statistical significance was assessed by two-way ANOVA with Holm-Sidak multiple comparisons to CD8+ T cells in A, and between two clustered groups at each dose in C. *, P < 0.05; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 4. Imatinib reduces eT reg cells and augments antitumor immune responses in vitro. (A) In vitro imatinib-dependent induction of tumor antigen–specific CD8+ T cells from PBMCs of healthy individuals. PBMCs from HLA-A*0201+ healthy individuals (n = 9) were stimulated with Melan-A26-35 peptide with/without 5 µM imatinib. Reduction of eT reg cells (top) and Melan-A–specific CD8+ T cell induction detected by MHC/Melan-A peptide tetramers (bottom). Representative result of three independent experiments. CD4+ and CD8+ T cells were separately analyzed by FACS. Summary of Melan-A–specific CD8+ T cell induction from nine healthy donors (right). (B) In vitro imatinib-dependent induction of tumor antigen–specific CD8+ T cells from PBMCs of cancer patients. PBMCs from two HLA-A*0201+ and one HLA-Cw*0304+ melanoma patients were stimulated with NY-ESO-1157–165 and NY-ESO-192–100 peptides, respectively, with/without 5 µM imatinib (n = 3). Decrease of eT reg cells (top) and increase of NY-ESO-1–specific CD8+ T cells detected by MHC/NY-ESO-1 peptide tetramers (bottom). Representative result of three independent experiments. CD4+ and CD8+ T cells were separately analyzed by FACS. Summary of NY-ESO-1–specific CD8+ T cell induction from three melanoma patients (right). Statistical significance was assessed by Student’s two-tailed paired t test in A and B.
Figure 4. Imatinib reduces eT reg cells and augments antitumor immune responses in vitro. (A) In vitro imatinib-dependent induction of tumor antigen–specific CD8+ T cells from PBMCs of healthy individuals. PBMCs from HLA-A*0201+ healthy individuals (n = 9) were stimulated with Melan-A26-35 peptide with/without 5 µM imatinib. Reduction of eT reg cells (top) and Melan-A–specific CD8+ T cell induction detected by MHC/Melan-A peptide tetramers (bottom). Representative result of three independent experiments. CD4+ and CD8+ T cells were separately analyzed by FACS. Summary of Melan-A–specific CD8+ T cell induction from nine healthy donors (right). (B) In vitro imatinib-dependent induction of tumor antigen–specific CD8+ T cells from PBMCs of cancer patients. PBMCs from two HLA-A*0201+ and one HLA-Cw*0304+ melanoma patients were stimulated with NY-ESO-1157–165 and NY-ESO-192–100 peptides, respectively, with/without 5 µM imatinib (n = 3). Decrease of eT reg cells (top) and increase of NY-ESO-1–specific CD8+ T cells detected by MHC/NY-ESO-1 peptide tetramers (bottom). Representative result of three independent experiments. CD4+ and CD8+ T cells were separately analyzed by FACS. Summary of NY-ESO-1–specific CD8+ T cell induction from three melanoma patients (right). Statistical significance was assessed by Student’s two-tailed paired t test in A and B.CC BY-NC-SA · PubMed Central
Figure 5. Imatinib-induced T reg cell reduction hinders growth of inoculated tumor in mice. (A) Tumor growth curve of BALB/c or BALB/c SCID mice inoculated with CT26 colon cancer. Mice were treated with imatinib at indicated doses for 5 d (n = 9 or 10 BALB/c or n = 8 or 9 SCID mice per each treatment group/experiment). Representative of two independent experiments. Tumor curves were assessed by two-way ANOVA, and asterisks by circles or squares indicate statistical significance between 0 and 10 mg/kg/d treated groups or 0 and 50 mg/kg/d treated groups for each time point, respectively. (B) The frequency of splenic (Spl) and tumor-infiltrating Foxp3+ T reg cells on the third day of imatinib treatment (10 d after tumor inoculation) as in A. Representative staining of each group (n = 3 or 4 mice per group). (C and D) Representative staining of Foxp3+CD4+ T cells in the tumor or the spleen for CD44 and CD62L (C, left) and the frequency of CD44hiCD62Llo FoxP3+ effector T reg cells in the tumor (C, right top) or the spleen (C, right bottom) 3 d after the last imatinib treatment (15 d after tumor inoculation). Representative staining of Foxp3+CD4+ T cells in the tumor or the spleen for CD44 and Ki-67 (D, left) and the frequency of Ki-67+CD44hi FoxP3+ T reg cells in the tumor (D, right top) or the spleen (D, right bottom) of the mice (n = 6 or 8 mice per group in two independent experiments). Error bars indicate means ± SEM in A or means ± SD in C and D. Statistical significance was assessed by two-way repeated-measure ANOVA with Tukey’s multiple comparisons test in A, or by two-sided Student’s t test in C and D.
Figure 5. Imatinib-induced T reg cell reduction hinders growth of inoculated tumor in mice. (A) Tumor growth curve of BALB/c or BALB/c SCID mice inoculated with CT26 colon cancer. Mice were treated with imatinib at indicated doses for 5 d (n = 9 or 10 BALB/c or n = 8 or 9 SCID mice per each treatment group/experiment). Representative of two independent experiments. Tumor curves were assessed by two-way ANOVA, and asterisks by circles or squares indicate statistical significance between 0 and 10 mg/kg/d treated groups or 0 and 50 mg/kg/d treated groups for each time point, respectively. (B) The frequency of splenic (Spl) and tumor-infiltrating Foxp3+ T reg cells on the third day of imatinib treatment (10 d after tumor inoculation) as in A. Representative staining of each group (n = 3 or 4 mice per group). (C and D) Representative staining of Foxp3+CD4+ T cells in the tumor or the spleen for CD44 and CD62L (C, left) and the frequency of CD44hiCD62Llo FoxP3+ effector T reg cells in the tumor (C, right top) or the spleen (C, right bottom) 3 d after the last imatinib treatment (15 d after tumor inoculation). Representative staining of Foxp3+CD4+ T cells in the tumor or the spleen for CD44 and Ki-67 (D, left) and the frequency of Ki-67+CD44hi FoxP3+ T reg cells in the tumor (D, right top) or the spleen (D, right bottom) of the mice (n = 6 or 8 mice per group in two independent experiments). Error bars indicate means ± SEM in A or means ± SD in C and D. Statistical significance was assessed by two-way repeated-measure ANOVA with Tukey’s multiple comparisons test in A, or by two-sided Student’s t test in C and D.CC BY-NC-SA · PubMed Central
Figure S5. Antitumor effect by imatinib in mice and molecular targets of imatinib in humans. (A) Total cell numbers of CD8+ and CD4+ T cells in the tumor (top) or the spleen (bottom) of CT26-inoculated BALB/c mice 3 d after the last imatinib treatment (15 d after tumor inoculation) as in Fig. 5 A. (B) The frequency and ratio of T reg cells and CD8+ T cells in Fig. 5 B. (C) Representative staining of Ki-67 and Foxp3 for CellTrace Violet+ T reg cells cultured with or without 10 µM imatinib and 5 U/ml IL-2 for 4 d. CD4+ Foxp3+ (GFP+) T reg cells from Foxp3-IRES-GFP reporter mice were sorted and labeled with CellTrace Violet before the culture (n = 3). Percentages of Ki-67+ cells (left) or mean fluorescence intensity of Foxp3 (right) are indicated in the plots. (D) Gene expression levels of putative targets of imatinib, including ABL1, ABL2, KIT, PDGFRA, LCK, NQO2,and DDR1 in human CD4+ or CD8+ T cells by deepCAGE (Cap Analysis of Gene Expression) database (CNhs 13223 and CNhs 12201). (E) LCK mRNA expressions in naive and effector subsets of CD8+ T, CD4+ T, and T reg cells prepared from PBMCs of healthy donors (n = 6). LCK mRNA levels relative to GAPDH were measured by quantitative real-time PCR. (F) FoxP3 binding near the promoter regions of human PIK3CD (gene encoding phosphatidylinositol-4,5-bisphosphate 3-kinase p110δ [PI3Kδ]) and PTPRC (gene encoding protein tyrosine phosphatase, receptor type C [CD45]) genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011). (G) Signal intensities of pY394-LCK and total LCK protein with or without 10 µM imatinib in Fig. 6 C. AU, arbitrary unit. Error bars indicate means ± SD. Data are pooled from at least two independent experiments. Statistical significance was evaluated by two-sided Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure S5. Antitumor effect by imatinib in mice and molecular targets of imatinib in humans. (A) Total cell numbers of CD8+ and CD4+ T cells in the tumor (top) or the spleen (bottom) of CT26-inoculated BALB/c mice 3 d after the last imatinib treatment (15 d after tumor inoculation) as in Fig. 5 A. (B) The frequency and ratio of T reg cells and CD8+ T cells in Fig. 5 B. (C) Representative staining of Ki-67 and Foxp3 for CellTrace Violet+ T reg cells cultured with or without 10 µM imatinib and 5 U/ml IL-2 for 4 d. CD4+ Foxp3+ (GFP+) T reg cells from Foxp3-IRES-GFP reporter mice were sorted and labeled with CellTrace Violet before the culture (n = 3). Percentages of Ki-67+ cells (left) or mean fluorescence intensity of Foxp3 (right) are indicated in the plots. (D) Gene expression levels of putative targets of imatinib, including ABL1, ABL2, KIT, PDGFRA, LCK, NQO2,and DDR1 in human CD4+ or CD8+ T cells by deepCAGE (Cap Analysis of Gene Expression) database (CNhs 13223 and CNhs 12201). (E) LCK mRNA expressions in naive and effector subsets of CD8+ T, CD4+ T, and T reg cells prepared from PBMCs of healthy donors (n = 6). LCK mRNA levels relative to GAPDH were measured by quantitative real-time PCR. (F) FoxP3 binding near the promoter regions of human PIK3CD (gene encoding phosphatidylinositol-4,5-bisphosphate 3-kinase p110δ [PI3Kδ]) and PTPRC (gene encoding protein tyrosine phosphatase, receptor type C [CD45]) genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011). (G) Signal intensities of pY394-LCK and total LCK protein with or without 10 µM imatinib in Fig. 6 C. AU, arbitrary unit. Error bars indicate means ± SD. Data are pooled from at least two independent experiments. Statistical significance was evaluated by two-sided Student’s t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.CC BY-NC-SA · PubMed Central
Figure 6. Imatinib inhibits LCK and selectively causes apoptosis in T reg cells. (A) LCK and ZAP-70 mRNA expressions in naive CD8+ T cells, Fr. I naive T reg cells, Fr. II eT reg cells, and naive CD4+ T cells prepared from PBMCs of healthy donors. LCK (n = 6) and ZAP-70 (n = 5) mRNA levels relative to GAPDH were measured by quantitative real-time PCR. Data are pooled from more than two independent experiments. (B) FoxP3 binding near the promoter regions of human LCK and ZAP-70 genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011) by Integrative Genomics Viewer software. (C) Total and phosphorylated LCK (pY394-LCK) protein expression measured by Western blotting. Each cell population sorted from PBMCs of healthy donors was incubated with or without 10 µM imatinib for 1 h (n = 5). Data are representative of five independent experiments. (D) Proliferation inhibition and apoptosis induction by the LCK inhibitor AMG-47a. Subsets of CD4+ T cells (Fr. I and II and FoxP3−CD4+ T cells) and CD8+ T cells prepared from PBMCs of healthy donors (n = 3) were stimulated with anti-CD3 and anti-CD28 mAbs with or without graded doses of AMG-47a for 5 d. Proliferation was assessed by CFSE dilution, and apoptosis was assessed by Annexin V and 7-AAD staining. IC50 for proliferation and EC50 for apoptosis are shown in the boxes. Data are pooled from more than two independent experiments. (E) Representative staining (n = 3 each) of Ki-67 in Fr. II eT reg cells from PBMCs of healthy donors treated with 10 µM imatinib or 250 nM AMG-47a for 4 d with anti-CD3 and anti-CD28 mAbs. Percentages of Ki-67+ cells were indicated. Data are pooled from more than two independent experiments. (F) The frequencies of cells with activated caspase 3 and 7, prepared from PBMCs of healthy donors, after treatment with or without 10 µM imatinib or 250 nM AMG-47a for 4 d with anti-CD3 and anti-CD28 mAbs. Caspase 3/7+ cells negative for SYTOX AADvanced cell impermeant nucleic acid stain were measured (n = 3 each). Data are pooled from more than two independent experiments. Error bars indicate means ± SEM in A, D, and F. Statistical significance was assessed by Student’s two-tailed paired t test in A and two-way ANOVA with Holm-Sidak multiple comparisons to CD8+ T cells in D, or to imatinib or AMG-47a–treated Fr. II T reg cells in F.
Figure 6. Imatinib inhibits LCK and selectively causes apoptosis in T reg cells. (A) LCK and ZAP-70 mRNA expressions in naive CD8+ T cells, Fr. I naive T reg cells, Fr. II eT reg cells, and naive CD4+ T cells prepared from PBMCs of healthy donors. LCK (n = 6) and ZAP-70 (n = 5) mRNA levels relative to GAPDH were measured by quantitative real-time PCR. Data are pooled from more than two independent experiments. (B) FoxP3 binding near the promoter regions of human LCK and ZAP-70 genes. The arrows indicate transcription start sites, boxes indicate exons, and peaks indicate FoxP3-binding sites from SRA data analysis (SRX060160; Birzele et al., 2011) by Integrative Genomics Viewer software. (C) Total and phosphorylated LCK (pY394-LCK) protein expression measured by Western blotting. Each cell population sorted from PBMCs of healthy donors was incubated with or without 10 µM imatinib for 1 h (n = 5). Data are representative of five independent experiments. (D) Proliferation inhibition and apoptosis induction by the LCK inhibitor AMG-47a. Subsets of CD4+ T cells (Fr. I and II and FoxP3−CD4+ T cells) and CD8+ T cells prepared from PBMCs of healthy donors (n = 3) were stimulated with anti-CD3 and anti-CD28 mAbs with or without graded doses of AMG-47a for 5 d. Proliferation was assessed by CFSE dilution, and apoptosis was assessed by Annexin V and 7-AAD staining. IC50 for proliferation and EC50 for apoptosis are shown in the boxes. Data are pooled from more than two independent experiments. (E) Representative staining (n = 3 each) of Ki-67 in Fr. II eT reg cells from PBMCs of healthy donors treated with 10 µM imatinib or 250 nM AMG-47a for 4 d with anti-CD3 and anti-CD28 mAbs. Percentages of Ki-67+ cells were indicated. Data are pooled from more than two independent experiments. (F) The frequencies of cells with activated caspase 3 and 7, prepared from PBMCs of healthy donors, after treatment with or without 10 µM imatinib or 250 nM AMG-47a for 4 d with anti-CD3 and anti-CD28 mAbs. Caspase 3/7+ cells negative for SYTOX AADvanced cell impermeant nucleic acid stain were measured (n = 3 each). Data are pooled from more than two independent experiments. Error bars indicate means ± SEM in A, D, and F. Statistical significance was assessed by Student’s two-tailed paired t test in A and two-way ANOVA with Holm-Sidak multiple comparisons to CD8+ T cells in D, or to imatinib or AMG-47a–treated Fr. II T reg cells in F.CC BY-NC-SA · PubMed Central
Figure 7. A schematic diagram showing direct or T cell–dependent killing of CML cells by imatinib for achieving CMR. Teff, effector T cell.
Figure 7. A schematic diagram showing direct or T cell–dependent killing of CML cells by imatinib for achieving CMR. Teff, effector T cell.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Metadata

Authors
Tanaka, A., Nishikawa, H., Noguchi, S., Sugiyama, D., Morikawa, H., Takeuchi, Y., Ha, D., Shigeta, N., Kitawaki, T., Maeda, Y., Saito, T., Shinohara, Y., Kameoka, Y., Iwaisako, K., Monma, F., Ohishi, K., Karbach, J., Jäger, E., Sawada, K., Katayama, N., Takahashi, N., & Sakaguchi, S.
Affiliations
  • Immunology Frontier Research Center, The University of Osaka (JP)
  • Akita University (JP)
  • Kyoto University (JP)
  • Mie University (JP)
  • Krankenhaus Nordwest (DE)
Corresponding author
Sakaguchi, Shimon
Venue
Journal of Experimental Medicine
Published
2019-11-08
Volume
217
Issue
2
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2989109767
Cited by
96
References
51
Citations by year
2026: 10 · 2025: 12 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 19 · 2020: 7
FWCI
4.49
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-sa)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology of Japan (16H06295, 26253030, 23300354, 26290054, 26860331, 17K15723, 17H06162)
  • Core Research for Evolutional Science and Technology
  • Japan Science and Technology Agency (17gm0410016)
  • Japan Agency for Medical Research and Development (18gm0010005, 18cm0106303)
  • Ministry of Health, Labor, and Welfare of Japan (H24-Clinical Cancer Research-general-006)
  • Cancer Research Institute
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
imatinib, tyrosine kinase inhibitors, regulatory T cells, Foxp3, Lck, ZAP-70, T cell receptor signaling, apoptosis, antitumor immunity, chronic myeloid leukemia, complete molecular remission, CD8+ T cells, melanoma, off-target effects
MeSH terms
Imatinib Mesylate, Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Immunity, Mice, Inbred BALB C, Mice, Transgenic, Receptors, Antigen, T-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, SCID, Treatment Outcome, Apoptosis, CD8-Positive T-Lymphocytes, Lymphocyte Specific Protein Tyrosine Kinase p56(lck), Cell Line, Tumor, Protein Kinase Inhibitors, T-Lymphocytes, Regulatory, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.